News

Clinical Trials Arena on MSN10d
AstraZeneca and Daiichi’s Enhertu shows pCR rate improvement in breast cancer trial
The trial’s primary endpoint is pCR, with secondary endpoints including event-free survival (EFS), overall survival, safety, ...
A Growth Factor Serum Might Be the Secret to Fighting Aging Without Irritation
In addition to buzzy ingredients like exosomes and PDRN, growth factor serums are another type of futuristic formula on the ...
Taiwan News5d
Ten-year APHINITY data show Roche’s Perjeta-based regimen reduced the risk of death by 17% in people with HER2-positive early-stage breast cancer
After ten years, results show: 91.6% of people treated with the Perjeta-based regimen were alive at ten years versus 89.8% of those treated with Herceptin, chemotherapy, and placebo (hazard ratio ...
PharmiWeb4d
Ten-year APHINITY data show Roche’s Perjeta-based…
Long term follow-up in this curative setting demonstrated clinically meaningful survival benefit when adding adjuvant Perjeta® (pertuzumab) to Herceptin® (trastuzumab) and chemotherapy121% reduction ...
The Pharma Letter5d
Ten-year APHINITY data show Roche’s Perjeta-based regimen reduced risk of death by 17%
Swiss pharma giant Roche (ROG: SIX), the Breast International Group (BIG), Institut Jules Bordet Clinical Trials Support Unit ...